Decitabine

Decitabine

File:Decitabine.svg
Clinical data
Pregnancy category	D
Routes of administration	Intravenous
Pharmacokinetic data
Protein binding	<1%
Elimination half-life	30 minutes
Identifiers
IUPAC name 4-amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)- 1,3,5-triazin-2(1H)-one
CAS Number	2353-33-5
PubChem CID	451668
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C8H12N4O4
Molar mass	228.0859 g/mol

WikiDoc Resources for Decitabine
Articles
Most recent articles on Decitabine Most cited articles on Decitabine Review articles on Decitabine Articles on Decitabine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Decitabine Images of Decitabine Photos of Decitabine Podcasts & MP3s on Decitabine Videos on Decitabine
Evidence Based Medicine
Cochrane Collaboration on Decitabine Bandolier on Decitabine TRIP on Decitabine
Clinical Trials
Ongoing Trials on Decitabine at Clinical Trials.gov Trial results on Decitabine Clinical Trials on Decitabine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Decitabine NICE Guidance on Decitabine NHS PRODIGY Guidance FDA on Decitabine CDC on Decitabine
Books
Books on Decitabine
News
Decitabine in the news Be alerted to news on Decitabine News trends on Decitabine
Commentary
Blogs on Decitabine
Definitions
Definitions of Decitabine
Patient Resources / Community
Patient resources on Decitabine Discussion groups on Decitabine Patient Handouts on Decitabine Directions to Hospitals Treating Decitabine Risk calculators and risk factors for Decitabine
Healthcare Provider Resources
Symptoms of Decitabine Causes & Risk Factors for Decitabine Diagnostic studies for Decitabine Treatment of Decitabine
Continuing Medical Education (CME)
CME Programs on Decitabine
International
Decitabine en Espanol Decitabine en Francais
Business
Decitabine in the Marketplace Patents on Decitabine
Experimental / Informatics
List of terms related to Decitabine

Overview

Decitabine (trade name Dacogen), or 5-aza-2'-deoxycytidine, is indicated for treatment of patients with myelodysplastic syndrome (MDS), including previously treated and untreated, de novo, and secondary MDS of all FAB subtypes and Intermediate-1, Intermediate-2, and High-Risk IPSS groups. It functions in the same way as 5-Azacytidine.

Basic information

• Trade Name: Dacogen
• Generic Name: decitabine
• FDA approved: May 2, 2006
• Classification: demethylating agent
• Manufacturer: MGI Pharma